1-20 of 40
Bingcheng Liu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ponatinib 2-Year Efficacy, Safety and Health-Related Quality of Life in Patients with Philadelphia Chromosome-Positive Leukemia: An Open-Label, Multicenter, Phase 2 Clinical Trial in China

Lu Yu, Huifang Wang, Xiaoli Liu, Bingcheng Liu, Xielan Zhao, Qun He, Qingshu Zeng, Zimin Sun, Ting Liu, Huanling Zhu, Zhuogang Liu, Xin Du, Jie Jin, Li Meng, Ming Hou, Suning Chen, Linhua Yang, Mingji Xian, Yoshitaka Kotobuki, Shuang Zhang, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 6602.
https://doi.org/10.1182/blood-2024-208258
Published: 2024
Journal Articles

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Li Weiming, Yanli Zhang, Huanling Zhu, Yunfan Yang, Na Xu, Bingcheng Liu, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu
Journal: Blood
Blood (2024) 144 (Supplement 1): 480.
https://doi.org/10.1182/blood-2024-204996
Published: 2024
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001

Qian Jiang, Li Weiming, Yanli Zhang, Qiang Wang, Suning Chen, Bingcheng Liu, Zhuogang Liu, Jie Jin, Zhenfang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Lie Lin, Wanlin Ye, Shujie Yan, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2024) 144 (Supplement 1): 477.
https://doi.org/10.1182/blood-2024-205300
Published: 2024
Journal Articles

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Runxia Gu, Xiaoyuan Gong, Dong Lin, Kaiqi Liu, Chunlin Zhou, Shuning Wei, Guangji Zhang, Benfa Gong, Yuntao Liu, Yan Li, Qiuyun Fang, Lihua Wu, Shouyun Li, Ying Wang, Hong Liu, Xiyan Wang, Shaowei Qiu, Bingcheng Liu, Hui Wei, Yingchang Mi, Jianxiang Wang, Wang Ying
Journal: Blood
Blood (2024) 144 (Supplement 1): 4199.
https://doi.org/10.1182/blood-2024-200713
Published: 2024
Journal Articles

Olverembatinib 30 Mg Versus 40 Mg Every Other Day (QOD) in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant or Intolerant Chronic-Phase Chronic Myeloid Leukemia (CML-CP): A Multi-Center Propensity Score-Matched Analysis

Xiaoshuai Zhang, Lu Yu, Li Zhou, Yanli Zhang, Huanling Zhu, Bingcheng Liu, Xin Du, Xiaodong Wang, Linhua Yang, Yanping Ma, Li Meng, Yanqing Zhang, Guohui Li, Lijie Yang, Baohong Wang, Xuehong Ran, Jian Huang, Qin Wen, Yan Wen, Yuxia Zhao, Yu Zhu, Yanqiu Han, Zhenfang Liu, Xin Du, Jianyu Weng, Qian Jiang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4529.
https://doi.org/10.1182/blood-2024-203533
Published: 2024
Journal Articles

Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, Shaowei Qiu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Shuning Wei, Guangji Zhang, Benfa Gong, Yuntao Liu, Yan Li, Shouyun Li, Bingcheng Liu, Wang Ying, Hui Wei, Yingchang Mi, Jianxiang Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 2812.
https://doi.org/10.1182/blood-2024-199109
Published: 2024
Journal Articles

Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1 st Line Imatinib

Bingcheng Liu, Ying Wang, Kaiqi Liu, Yan Li, Qiuyun Fang, Yuntao Liu, Xiaoyuan Gong, Chunlin Zhou, Benfa Gong, Guangji Zhang, Shaowei Qiu, Hui Wei, Yingchang Mi, Jianxiang Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 4533.
https://doi.org/10.1182/blood-2024-204887
Published: 2024
Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Clinical Trials & Observations
Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Yanli Zhang, Na Xu, Robert Peter Gale, Weiming Li, Xiaoli Liu, Huanling Zhu, Ling Pan, Yunfan Yang, Hai Lin, Xin Du, Rong Liang, Chunyan Chen, Xiaodong Wang, Guohui Li, Zhuogang Liu, Yanqing Zhang, Zhenfang Liu, Jianda Hu, Chunshui Liu, Fei Li, Wei Yang, Li Meng, Yanqiu Han, Li’e Lin, Zhenyu Zhao, Chuanqing Tu, Caifeng Zheng, Yanliang Bai, Zeping Zhou, Suning Chen, Huiying Qiu, Lijie Yang, Xiuli Sun, Hui Sun, Li Zhou, Zelin Liu, Danyu Wang, Jianxin Guo, Liping Pang, Qingshu Zeng, Xiaohui Suo, Weihua Zhang, Yuanjun Zheng, Xiaojun Huang, Qian Jiang
Journal: Blood
Blood (2024) 144 (18): 1951–1961.
https://doi.org/10.1182/blood.2024024761
Published: 2024
Includes: Supplemental data
Journal Articles

Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Suning Chen, Yanli Zhang, Na Xu, Hui Sun, Li Weiming, Yunfan Yang, Zunmin Zhu, Minghui Duan, Sixuan Qian, Yu Zhu, Jianmin Luo, Xiaodong Wang, Wei Yang, Weiying Gu, Fei Li, Bingcheng Liu, Yunxiao Xu, Zhenfang Liu, Chunling Wang, Yirong Jiang, Li Meng, Qin Wen, Yanli Xu, Xingli Zou, Wei Wang, Yan Xue, Hao Xu, Kehong Bi, Fuling Zhou, Liangming Ma, Rong Fu, Guifang Ouyang, Kaiyang Ding, Depei Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1797.
https://doi.org/10.1182/blood-2023-179073
Published: 2023
Journal Articles

Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study

Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, Shaowei Qiu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Guangji Zhang, Benfa Gong, Yuntao Liu, Shuning Wei, Yan Li, Shouyun Li, Bingcheng Liu, Yimin Hu, Junfan Li, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 827.
https://doi.org/10.1182/blood-2023-184421
Published: 2023
Journal Articles

RTK-RAS Signaling Pathway Was Enriched in Rare Acute Myeloid Leukemia Patients with t(16;21)(p11;q22)/ FUS::ERG

Anli Lai, Hui Wei, Ying Wang, Dong Lin, Chunlin Zhou, Bingcheng Liu, Runxia Gu, Yan Li, Shuning Wei, Benfa Gong, Kaiqi Liu, Xiaoyuan Gong, Yuntao Liu, Guangji Zhang, Junping Zhang, Yingchang Mi, Shaowei Qiu, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5988.
https://doi.org/10.1182/blood-2023-179966
Published: 2023
Journal Articles

A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia

Xiao-shuai Zhang, Bingcheng Liu, Jian Huang, Xin Du, Yanli Zhang, Na Xu, Xiaoli Liu, Li Weiming, Hai Lin, Huanling Zhu, Yunfan Yang, Ling Pan, Xiao-jun Huang, Qian Jiang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3167.
https://doi.org/10.1182/blood-2023-185473
Published: 2023
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study

Qian Jiang, Yanli Zhang, Qiang Wang, Jianyu Weng, Zhenfang Liu, Suning Chen, Li Weiming, Bingcheng Liu, Zhuogang Liu, Yihan Wang, Jingrong Cao
Journal: Blood
Blood (2023) 142 (Supplement 1): 867.
https://doi.org/10.1182/blood-2023-185977
Published: 2023
Journal Articles

Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib

Yuntao Liu, Yunfan Yang, Hui Sun, Li Meng, Hai Lin, Chunyan Chen, Jianda Hu, Xuliang Shen, Minghui Duan, Yanli Zhang, Dilinazi Abulaiti, Jinghua Wang, Hongqian Zhu, Luoming Hua, Qing Leng, Chun Zhang, Lili Sun, Weiming Li, Huanling Zhu, Bingcheng Liu, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6367.
https://doi.org/10.1182/blood-2023-190780
Published: 2023
Journal Articles

The Impact of ZNF384 Rearranged on Antigen Editing during Treatment-Specific Selective Pressures in Adult B Cell Acute Lymphoid Leukemia

Runxia Gu, Wenbin Liu, Yihan Mei, Le Li, Chunlin Zhou, Yan Li, Yuntao Liu, Shuning Wei, Dong Lin, Kaiqi Liu, Qiuyun Fang, Xiaoyuan Gong, Benfa Gong, Shaowei Qiu, Bingcheng Liu, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 4209.
https://doi.org/10.1182/blood-2023-188950
Published: 2023
Journal Articles

Prognostic Value of MRD By Flow Cytometry in Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia Treated with Pediatric-Inspired Regimen: A Post-Hoc Analysis from a Prospective Study of China

Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, Shaowei Qiu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Guangji Zhang, Benfa Gong, Yuntao Liu, Yan Li, Shouyun Li, Bingcheng Liu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6073.
https://doi.org/10.1182/blood-2023-174856
Published: 2023
Journal Articles

Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

Congxiao Zhang, Runxia Gu, Chunlin Zhou, Yan Li, Yuntao Liu, Shuning Wei, Dong Lin, Benfa Gong, Kaiqi Liu, Qiuyun Fang, Xiaoyuan Gong, Shaowei Qiu, Bingcheng Liu, Ying Wang, Hui Wei, Yingchang Mi, Jianxiang Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 2030–2032.
https://doi.org/10.1182/blood-2022-162459
Published: 2022
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022
Journal Articles

A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China

Qian Jiang, Zongru Li, Ya-Zhen Qin, Ting Zhao, Bingcheng Liu, Zi Chen, Qian Niu, Lichuang Men, Hengbang Wang, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 198–199.
https://doi.org/10.1182/blood-2022-170868
Published: 2022